Sentences with phrase «year price earnings»

Something I read last week got me interested in Professor Robert Shiller's use of the 10 year price earnings ratio

Something I read last week got me interested in Professor Robert Shiller's use of the 10 year price earnings ratio (PE) to value the stock market.

Not exact matches

The forward price / earnings ratio of the top 25 % of S&P 500 stocks by dividend yield is 17, vs. a 36 - year average of 12, according to Ned Davis Research.

Huber of T. Rowe Price foresees high - single - digit earnings - per - share growth, and 15 % share - price upside in the next couple of years, even before factoring in yPrice foresees high - single - digit earnings - per - share growth, and 15 % share - price upside in the next couple of years, even before factoring in yprice upside in the next couple of years, even before factoring in yield.

The fundamentals for the bank stocks are remarkably similar to where they were last year, with dividend yields and price - to - earnings ratios virtually unchanged.

That's according to Goldman Sachs, which also notes that the options market isn't adequately priced for the stock fluctuations that are likely to come, despite the huge number of earnings preannouncements made during the first month of the year.

For the full year, Exxon reported profits of $ 19.71 billion, its highest annual earnings since the start of an oil price slide in 2014, when it earned $ 32.52 billion.

Shiller's CAPE ratio measures the stock price divided by the average of ten years of earnings, adjusted for inflation.

The firm says the option market is pricing in an earnings - related move of 3.6 %, above its three - year average realized move of 2.5 %.

But the firm still ended its 2015 fiscal year on an upswing, with revenues up by 10 %, earnings up 17 % to $ 70.2 million and the stock price back up in the $ 25 range.

Earnings growth has been the foremost driver of stock price appreciation throughout the nine - year bull market — but what happens if it slows down?

Royal Dutch / Shell and BP on Tuesday joined peers in reporting higher than expected earnings by making further deep cuts in spending to cope with an oil price downturn now in its third year.

He also points out that company is trading at a 16 times 2015 price - to - earnings multiples, which is near the mid-point of the stock's five year historical trading range.

Its average forward price - to - earnings ratio has been 13 over the past two years.

European earnings are expected to rise this year as growth improves, the euro weakens and commodity prices strengthen.

Then, after a year, the stock price grows to $ 15 based on improved earnings.

Dziuba thinks it can grow earnings by 20 % a year, and predicts its stock price will climb from $ 20 today to about $ 34.

«Latest estimates show that average weekly earnings for employees in Great Britain in real terms (that is, adjusted for price inflation) fell by 0.7 % including bonuses, and fell by 0.5 % excluding bonuses, compared with a year earlier,» the ONS said.

Over that past 20 years, the price - to - earnings ratio of the Nasdaq Biotechnology Index has averaged 2.3 times the S&P 500 P / E ratio; today, the current ratio is mere 1.3 x, a 54 percent discount to its 20 - year average (according to Thomson Reuters, as of Sept. 26, 2017.)

There are only a handful of times over the past 20 years that the Standard & Poor's 500 and the S&P / TSX composite index have had price - to - earnings ratios this low.

Richards's target price for RIM is $ 72, or, as he points out just «10 times this year's earnings per share,» a valuation he calls «ridiculous.»

Our 2013 year - end target of 1600 implies a 10 % price return, where most of the appreciation can be attributed to earnings growth of 7 % next year, along with modest multiple expansion from 14.2 x to 14.7 x on trailing earnings, still below an average PE of 16x.

Buyers say better - than - expected earnings, as well as lower prices at the pump and relatively positive economic data provide three powerful catalysts that should drive a slow churn higher into the end of the year.

Actual results, including with respect to our targets and prospects, could differ materially due to a number of factors, including the risk that we may not obtain sufficient orders to achieve our targeted revenues; price competition in key markets; the risk that we or our channel partners are not able to develop and expand customer bases and accurately anticipate demand from end customers, which can result in increased inventory and reduced orders as we experience wide fluctuations in supply and demand; the risk that our commercial Lighting Products results will continue to suffer if new issues arise regarding issues related to product quality for this business; the risk that we may experience production difficulties that preclude us from shipping sufficient quantities to meet customer orders or that result in higher production costs and lower margins; our ability to lower costs; the risk that our results will suffer if we are unable to balance fluctuations in customer demand and capacity, including bringing on additional capacity on a timely basis to meet customer demand; the risk that longer manufacturing lead times may cause customers to fulfill their orders with a competitor's products instead; the risk that the economic and political uncertainty caused by the proposed tariffs by the United States on Chinese goods, and any corresponding Chinese tariffs in response, may negatively impact demand for our products; product mix; risks associated with the ramp - up of production of our new products, and our entry into new business channels different from those in which we have historically operated; the risk that customers do not maintain their favorable perception of our brand and products, resulting in lower demand for our products; the risk that our products fail to perform or fail to meet customer requirements or expectations, resulting in significant additional costs, including costs associated with warranty returns or the potential recall of our products; ongoing uncertainty in global economic conditions, infrastructure development or customer demand that could negatively affect product demand, collectability of receivables and other related matters as consumers and businesses may defer purchases or payments, or default on payments; risks resulting from the concentration of our business among few customers, including the risk that customers may reduce or cancel orders or fail to honor purchase commitments; the risk that we are not able to enter into acceptable contractual arrangements with the significant customers of the acquired Infineon RF Power business or otherwise not fully realize anticipated benefits of the transaction; the risk that retail customers may alter promotional pricing, increase promotion of a competitor's products over our products or reduce their inventory levels, all of which could negatively affect product demand; the risk that our investments may experience periods of significant stock price volatility causing us to recognize fair value losses on our investment; the risk posed by managing an increasingly complex supply chain that has the ability to supply a sufficient quantity of raw materials, subsystems and finished products with the required specifications and quality; the risk we may be required to record a significant charge to earnings if our goodwill or amortizable assets become impaired; risks relating to confidential information theft or misuse, including through cyber-attacks or cyber intrusion; our ability to complete development and commercialization of products under development, such as our pipeline of Wolfspeed products, improved LED chips, LED components, and LED lighting products risks related to our multi-year warranty periods for LED lighting products; risks associated with acquisitions, divestitures, joint ventures or investments generally; the rapid development of new technology and competing products that may impair demand or render our products obsolete; the potential lack of customer acceptance for our products; risks associated with ongoing litigation; and other factors discussed in our filings with the Securities and Exchange Commission (SEC), including our report on Form 10 - K for the fiscal year ended June 25, 2017, and subsequent reports filed with the SEC.

COPENHAGEN, Feb 1 - Novo Nordisk operating profit fell short of expectations in the fourth quarter as it felt the effects of price pressure in the United States and it warned that a weak dollar would hit earnings this year more than expected.

Morgan Stanley lowered its ratings on several chip stocks, citing lower flash memory prices and meager earnings growth next year.

Morgan Stanley lowers its ratings on several chip stocks, citing lower flash memory prices and meager earnings growth next year.

The S&P 500's forward price - to - earnings ratio has slid from 18.6 on Jan. 26 to 17 on Feb. 5 to 16.2 entering this week — and 16.2 also happens to be exactly the five - year average multiple.

Looking at annual price returns over the past 60 years, Bloomberg data show that annual price returns have been roughly 5 percent when the starting valuation on the S&P 500 was above the long - term median, roughly 16.5 x trailing earnings.

«The stock prices are still not reflecting the earnings power that's likely to show up here in this quarter and for the year as a whole,» said Leo Grohowski, chief investment officer at BNY Mellon Wealth Management, which has been overweight the energy sector.

Because PE is a measure of earnings over time, you can think of it as representing the number of years required to pay back a stock's purchase price (ignoring inflation, earnings growth and the time value of money).

This year's Fortune 500 generated a total of $ 944.5 billion in earnings, which are down 12.6 % from last year's record of $ 1.08 trillion, in large part because tumbling oil prices took a toll on the majority of the companies on the list.

The miner said adjusted net earnings for the quarter ended March 31 rose to $ 170 million, or 15 cents a share, from $ 162 million or 14 cents a share in the same three - month period a year ago on the back of higher gold prices and lower depreciation.

In its most recent earnings report, Mattel said Hot Wheels» performance this year has been strong, as the brand is one of its three most important along with Barbie and Fisher Price.

RIM stock shed 4.6 % of its value the night of the earnings call, continuing a slide that's seen share prices tumble almost 30 % so far this year.

Our 12 - month forward target for year - end 2015 is 2275, offering about 10 % upside to today's price, based on 7 % earnings growth in 2015 and 2016 and modest further multiple expansion to near 17x forward earnings... Multiple higher?

Suncor said that while the discount Canadian producers face nearly doubled in the first quarter compared with last year's quarter, it had no impact on the company's earnings or cash flow, as low crude prices were offset by better midstream and downstream returns.

«Our 12 - month forward target for year - end 2015 is 2275, offering about 10 % upside to today's price, based on 7 % earnings growth in 2015 and 2016 and modest further multiple expansion to near 17x forward earnings.»

We forecast a 2015 year - end S&P 500 price of 2,225 on the back of earnings growth and modest multiple expansion, typical in a maturing rally.»

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Norwegian consumer goods maker Orkla sank 7.7 percent, its worst fall in five years, after reporting that higher raw - material prices caused its earnings to miss expectations.

The Shiller price / earnings ratio, which compares companies» share prices with their inflation - adjusted 10 - year earnings average, is at 31, well above the historical median of 16 — a sign that future returns will be sluggish.

Nintendo's stock looks relatively affordable despite its recent gains, with its American depositary receipt trading at a price - to - earnings ratio that's less than half its five - year average.

When Tribune Publishing holds its quarterly earnings call on Thursday, its stock price will likely have plummeted more than 50 percent since the beginning of the year.

According to a Bain analysis, 45 % of TSR growth at publicly traded global healthcare companies over the past five years came from an expansion of price - to - earnings multiples — that is more than growth from either revenue or earnings.

At the point the growth began to slow, the multiple would contract, meaning that even if its earnings do grow 600 % in the next few years, if it becomes subject to the law of big numbers - that ever increasing amounts eventually forge their own anchor - the result would be a market capitalization substantially similar to today, leading to no increase in the stock price over a long period of time.

Existing home sales are up 9.7 percent over a year ago, new home prices touch record highs and Matt Phillips says the hidden indicators on housing are buried in Home Depot's «rock solid» earnings.

Once you began to generate profit, the price to earnings ratio would understate the amount of money you had available in subsequent years to put to work in expansion, whereas the price to cash flow ratio would more accurately describe the situation.

Right now with earnings growth very strong and the bond market already reflecting a fair amount of Fed tightening (pricing in 5 rate hikes over the coming 2 years), my sense is that the stock market is in OK shape to withstand some tightening of financial conditions and not unravel in the process.

Benjamin Graham was fond of averaging profit per share for the past seven years to balance out highs and lows in the economy because, if you attempted to measure the p / e ratio without it, you'd get a situation where profits collapse a lot faster than stock prices making the price - to - earnings ratio look obscenely high when, in fact, it was low.